HutchMed (China) Limited (NASDAQ: HCM; HKG: 0013) announced that regulatory applications for the combination therapy of Orpathys (savolitinib) and Tagrisso (osimertinib) have been accepted for review in Europe and Japan. The filings are supported by pivotal data showing that the combination delivered statistically significant and clinically meaningful improvements in progression‑free survival (PFS) and overall survival (OS) versus platinum‑based doublet chemotherapy in patients with disease progression following Tagrisso treatment.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agencies | Regulatory authorities in Europe and Japan |
| Filing Status | Accepted for review – announced 2 Nov 2026 |
| Products | Orpathys (savolitinib) + Tagrisso (osimertinib) combination therapy |
| Target Population | Patients with disease progression following Tagrisso treatment |
| Comparator | Platinum‑based doublet chemotherapy |
| Review Decision Dates | Not disclosed |
Drug Profile & Mechanism of Action
- Orpathys (savolitinib): A potent, highly selective oral MET tyrosine kinase inhibitor (TKI) with demonstrated clinical activity in advanced solid tumors. It blocks abnormal activation of the MET receptor tyrosine kinase signaling pathway caused by mutations (such as exon 14 skipping mutations or other point mutations), gene amplification, or protein overexpression. Co‑developed by AstraZeneca and HutchMed and commercialized by AstraZeneca.
- Tagrisso (osimertinib): An irreversible third‑generation EGFR‑TKI with established clinical activity in non‑small cell lung cancer (NSCLC), including patients with central nervous system (CNS) metastases.
- Combination Rationale: MET pathway activation is a recognized resistance mechanism following EGFR‑TKI therapy; pairing the MET‑selective inhibitor Orpathys with the EGFR inhibitor Tagrisso simultaneously targets both oncogenic drivers in the post‑progression setting.
Clinical Evidence – Combination Versus Chemotherapy
| Endpoint | Result (Orpathys + Tagrisso) | Comparator (Platinum Doublet Chemotherapy) | Relative Benefit |
|---|---|---|---|
| Disease Progression or Death (PFS) | Risk reduced 45% | – | Statistically significant and clinically meaningful |
| Median PFS (BICR) | 7.6 months | 5.4 months | +2.2 months |
| Overall Survival (Key Secondary) | Risk of death reduced 32% | – | Statistically significant improvement |
PFS was assessed by Blinded Independent Central Review (BICR). Together, the PFS and OS results form the pivotal evidence base supporting the European and Japanese regulatory submissions for patients whose disease progresses after Tagrisso – a population with high unmet need and limited effective options beyond chemotherapy.
Market Impact & Outlook
- Global Label Expansion: Review acceptances in Europe and Japan extend the combination’s regulatory footprint beyond existing markets, with decision timelines not yet disclosed.
- Post‑Resistance Standard of Care Potential: A 45% reduction in the risk of progression or death and a 32% reduction in the risk of death versus chemotherapy position Orpathys plus Tagrisso as a targeted alternative in the difficult post‑EGFR‑TKI progression setting.
- Partnership Economics: With Orpathys commercialized by AstraZeneca and co‑developed with HutchMed, approvals in Europe and Japan would deepen the value of the collaboration and expand HutchMed’s royalty and milestone streams.
- Precision Oncology Franchise: The filings reinforce the MET/EGFR dual‑targeting strategy as a differentiated approach to acquired resistance in NSCLC, one of the largest oncology markets worldwide.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding regulatory review outcomes in Europe and Japan, approval timelines, and commercial expectations for the Orpathys plus Tagrisso combination. Actual results may differ materially due to risks including regulatory review decisions, additional data requirements, competitive dynamics, and commercialization execution. Clinical results are as reported in the company’s 2 Nov 2026 announcement.-Fineline Info & Tech
